Pre-made Tositumomab benchmark antibody (Radiolabelled antibody, anti-MS4A1/CD20 therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Tositumomab benchmark antibody (Radiolabelled antibody, anti-MS4A1/CD20 therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tositumomab is a murine monoclonal antibody which targets the CD2 antigen produced in mammalian cell.[1] It was combined with iodine-131 to produce a radiopharmaceutical for unsealed source radiotherapy, Iodine-131 Tositumomab (branded as Bexxar), for the treatment of non-Hodgkins lymphoma.[1] It is classified as a IgG2a lambda antibody.[1][2]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-1028-1mg	1mg	3090
GMP-Bios-INN-1028-10mg	10mg	Inquiry
GMP-Bios-INN-1028-100mg	100mg	Inquiry
GMP-Bios-INN-1028-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Tositumomab Biosimilar, Radiolabelled Antibody, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
INN Name	Tositumomab
Target	MS4A1/CD20
Format	Radiolabelled antibody
Derivation	Mus musculus
Species Reactivity	human
CH1 Isotype	IgG2a - lambda
VD LC	IgG2a - lambda
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	GlaxoSmithKline (Brentford UK) / Corixa Corp. (Seattle WA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0